Xuantai Medicine Co., Ltd. (688247.SH): The approval number for the slow-release tablet of Dapagliflozin Metformin has been obtained from the US FDA.

Financial news app Jitong reports that Xuantai Pharmaceuticals (688247.SH) announced recently that the company had received a notification from the U.S. Food and Drug Administration (FDA) that its Abbreviated New Drug Application (ANDA) for the generic version of Dapagliflozin Metformin extended-release tablets has been tentatively approved.